Liver Warning with Prezista
Tibotec Dear Healthcare Professional: IMPORTANT DRUG WARNING March 2008Dear Healthcare Professional: Tibotec Therapeutics, in cooperation with the U.S. Food and Drug Administration, would like to inform you of an important update to the prescribing information for PREZISTA TM (darunavir) tablets regarding addition of a Warning on Hepatotoxicity. In clinical trials and postmarketing experience, drug-induced hepatitis […]
Liver Warning with Prezista Read More »